Key elements of our strategy are to:
Continue to leverage our expertise in discovering and designing highly selective small molecules while advancing our early-stage biologic drug candidates.
A primary objective of our drug discovery team’s efforts has been, and will continue to be, to use our expertise in advanced medicinal chemistry to develop next-generation tyrosine kinase inhibitors that have both high selectivity and superior pharmacokinetic properties. Equally importantly, we will continue to design drug candidates with profiles that enable them to be used in innovative combinations with other selective inhibitors, chemotherapy agents and immunotherapies.
We further plan to enrich our global pipeline of self-discovered drug candidates by advancing a broad range of early-stage drug candidates, which include biologics addressing novel targets designed for use in combination with our small molecules as well as potentially a broad range of third-party therapies.
Advance the global clinical programs of our multiple potential first-in-class and best-in-class drug candidates.
We plan to accelerate global development of our four unpartnered drug candidates: fruquintinib (ex-China), surufatinib, HMPL-523 and HMPL-689. Together with AstraZeneca, we intend to advance global development of savolitinib in combination with Tagrisso.
To broaden and scale our international operations and support our increasing clinical activities in the United States and Europe, we also plan to significantly expand our newly established U.S. clinical team.
Capitalize on regulatory reforms currently underway in China aimed at addressing existing major unmet medical needs and improving the health of its people.
Having invested in drug innovation in China for over 17 years, we are well positioned to capture the opportunity in the rapidly growing oncology drug market in China. Supported by China’s improving regulatory environment, we intend to rapidly advance our eight clinical-stage drug candidates to meet the country’s significant unmet medical needs.
Leverage expertise and know-how of our commercial infrastructure in China to support commercialization of our innovative drug candidates.
Our Commercial Platform and its sales and marketing infrastructure stood at over 3,500 total sales staff for prescription drugs and over-the-counter products at the end of 2018. We will particularly look to further build an oncology-focused sales team within our Prescription Drugs business to commercialize drugs developed by our Innovation Platform if they are approved for sale in China.
Outside of China, we intend to commercialize our products, if approved, in the United States, Europe and other major markets on our own and/or through partnerships with leading biopharmaceutical companies.
Identify global business development and strategic acquisition opportunities to complement our internal research and development activities, while continuing to adapt existing collaborations as necessary.
We expect to further expand our portfolio of drug candidates in oncological and immunological therapeutic areas by pursuing business development opportunities with other biopharmaceutical companies both in China and globally.
We will also continue to work with our partners, AstraZeneca and Eli Lilly, to develop our partnered drug candidates savolitinib (global) and fruquintinib (in China) and seek to optimize the terms of these collaborations in the future to the extent possible in order to foster the further development of such drugs.